CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

PozelimabWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug2832 Taste and olfactory function evaluation Wiki 1.00
drug1835 Nasal swab Wiki 0.71

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Randomized, Open-Label, Parallel Group Study of the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Subjects

The primary objective of the study is to compare the pharmacokinetic(PK) profile of pozelimab produced by the original manufacturing process (Process A) compared to a second manufacturing process (Process B) The secondary objectives of the study are: - Assess the safety and tolerability of a single SC dose of pozelimab produced by the 2 manufacturing processes - Assess the immunogenicity of pozelimab produced by the 2 manufacturing processes

NCT04491838 Healthy Volunteer Drug: Pozelimab

Primary Outcomes

Measure: Assess the time of the last positive concentration (AUClast) pharmacokinetic (PK) profile of pozelimab in Process A

Time: Up to 16 weeks

Measure: Assess the time of the last positive concentration (AUClast) PK profile of pozelimab in Process B

Time: Up to 16 weeks

Measure: Assess peak concentration (Cmax) PK profile of pozelimabin in Process A

Time: Up to 16 weeks

Measure: Assess peak concentration (Cmax) PK profile of pozelimab in Process B

Time: Up to 16 weeks

Secondary Outcomes

Measure: Incidence of treatment emergent adverse events (TEAEs)

Time: Up to 16 weeks

Measure: Incidence of anti-drug antibodies (ADA) to pozelimab over time

Time: Up to 16 weeks

No related HPO nodes (Using clinical trials)